Chemotherapy and targeted therapy before surgery for colorectal cancer
Part of Cancer, Digestive system clinical trials.
This study looks at using a combination of chemotherapy and a targeted therapy (fruquintinib) before surgery for colorectal cancer. The goal is to see if this approach can shrink tumors and improve outcomes for patients with different stages of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with colorectal cancer.
- For the neoadjuvant group: you have not had any previous cancer treatment (like chemo, radiation, or targeted therapy) and your cancer is stage II, III, or has limited spread to the liver that can be surgically removed.
- For the conversion group: your cancer is initially not removable but might become removable after treatment, or you have low rectal cancer and cannot or do not want to have standard chemoradiation.
- You have already received at least 2 cycles of chemotherapy plus fruquintinib as part of your treatment plan.
- You are in good general health (able to care for yourself) and have a life expectancy of more than 3 to 6 months.
- You do not have certain genetic markers (dMMR/MSI-H) that would make this treatment less likely to work.
- You are not pregnant or breastfeeding, and you have no known severe allergies to the study drugs.
- You are willing to come back for follow-up visits and tumor assessments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (cadonilimab, fruquintinib) plus targeted radiation (SBRT) for people with advanced MSS colorectal cancer who have already tried several standard treatments. The goal is to see if this combination can help shrink tumors or slow disease progression.
This trial is testing a new combination of two oral cancer drugs (fruquintinib and S-1) in people with metastatic colorectal cancer who have already had at least one prior chemotherapy. The goal is to see if this combination helps shrink or slow the growth of tumors.
This trial tests a drug called fruquintinib, given alone or with a chemotherapy infusion directly into your liver, for people whose colorectal cancer has spread to the liver and has stopped responding to standard treatments. It aims to find a new option for patients with limited cancer outside the liver.
This trial tests whether the combination of fruquintinib with chemotherapy (trifluridine/tipiracil) works as well as or better than the current standard of bevacizumab with the same chemotherapy for advanced colorectal cancer that has spread. It is for patients who have already had several lines of treatment and are looking for new options.
This trial tests whether adding TAS-102 to fruquintinib works better than fruquintinib alone for people with advanced colorectal cancer that has stopped responding to other treatments.
This trial studies fruquintinib combined with serplulimab (an immune therapy) for advanced colorectal cancer that has spread and is no longer responding to standard treatments. It may help by slowing the cancer’s growth and improving outcomes after the usual options have been tried.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.